Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide ...

British Pound US Dollar, Chevron Corp, McDonald’s Corporation, Apple Inc. Read 's Market Analysis on Investing.com ...

China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading ...

Still too few directors recognise AI’s potential to improve preparation, discussion and decision-making in the boardroom. But ...

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo ...

Eli Lilly and Company (NYSE: LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his ...